Here are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.
Matthew A. Lunning, MD
Advertisement
Articles by Matthew A. Lunning, MD
DLBCL is a genetically heterogeneous malignancy with multiple subtypes and recent investigations based on molecular profiles have opened the possibility for personalized therapy in this disease space.
This review article written by Meghana Kesireddy, MBBS and Matthew A. Lunning, MD, reviews management and treatment of relapsed/refractory large B-cell lymphoma.
Advertisement
Latest Updated Articles
Relapsed or Refractory Diffuse Large B-Cell Lymphoma: “Dazed and Confused”Published: June 16th 2022 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research
2
Could Scorpion Venom Component Play a Role in Glioblastoma Management?
3
Novel IL-2 Therapy Combo Yields Initial Responses in Nonsquamous NSCLC
4
What Were The Most Impactful GU Oncology Data From ESMO 2025?
5
